Papillary Microcarcinoma: Active Surveillance vs Surgery

Papillary microcarcinoma (PTMC) — papillary thyroid carcinoma ≤1 cm. The WHO size threshold defines this "low-risk" subgroup. Incidence has dramatically increased with widespread screening (autopsy series show 5-36% — meaning many people carry it without clinical impact).

Clinical vs subclinical: most PTMCs are subclinical — never detected during life, never cause symptoms. The screening era (neck US, incidental CT/MRI) has dramatically increased incidence without changing mortality. A classic "overdiagnosis" phenomenon.

Risk spectrum: most labelled PTMC behave indolently. Some aggressive variants — tall cell, hobnail, columnar, diffuse sclerosing — behave aggressively even at small size. Histopathology is therefore key.

In Turkey: thyroid cancer incidence has risen 3-4 fold over the last 20 years (largely PTMC), mirroring global trends. Female:male 3:1. Mortality stable — most added cases are not clinically significant.

Birth of active surveillance: 1990s at Kuma Hospital (Japan) — Drs Akira Miyauchi and Yasuhiro Ito offered observation as an alternative to surgery in PTMC. The 30+ year dataset is now the global reference. Memorial Sloan Kettering and other centres have published similar protocols.

ATA 2015 (American Thyroid Association) guideline: active surveillance is accepted as an alternative in selected PTMC — a paradigm shift. We expand on the clinical framework in our thyroid surgery programme.

Kuma Hospital cohort (1993-present): 1465 low-risk PTMC patients; 10-year outcomes (Ito et al): tumour size growth ≥3 mm — 5.4%; new nodal metastasis — 1.7%; distant metastasis — 0%; disease-specific death — 0%; conversion to surgery during follow-up — 7-8%.

Key note: among patients who eventually had surgery, no deaths occurred; no patient is "lost". Delayed surgery does not become life-threatening.

Memorial Sloan Kettering cohort (2014-): similar selection criteria; 5-year data support Kuma findings.

Korea Asan Medical Centre cohort: 192 patients; similar low growth, zero mortality.

Korean multicentre — Lee et al 2018: 369 patients; 5-year growth ≥3 mm — 4.6%; new nodal — 0.5%.

Tessler/Ito meta-analysis: pooled active surveillance cohorts; 10-year growth 4-10%, nodal recurrence 1-2%, mortality 0%.

These data underlie ATA 2015 — "active surveillance is an acceptable alternative for selected low-risk PTMC". Turkish national thyroid guidelines also list this option (with expert evaluation prioritised).

Patient outcomes (quality of life): the non-surgical group avoids surgical complications (recurrent laryngeal nerve palsy, hypoparathyroidism, scar, lifelong levothyroxine); but surveillance stress exists — some studies show increased depression and anxiety ("I have cancer but we are watching" can be uncomfortable). This is a selection factor.

Suitable for active surveillance (ATA 2015 + Japanese consensus): 1) Tumour ≤1 cm with low-risk US features — confined to lobe, no capsule contact, not adjacent to trachea or recurrent laryngeal nerve. 2) Clinically N0 — no preoperative nodal metastasis on neck US. 3) M0 — no distant metastasis. 4) No aggressive histology — classical papillary; not tall cell, hobnail, columnar, sclerosing. 5) No strong family history (no syndromic). 6) Patient suitable for regular follow-up, connected to a capable centre.

Not suitable for surveillance: 1) Tumour >1 cm (PTC, not microcarcinoma) — surgery standard. 2) High-risk US features — capsule penetration, tracheal/nerve adjacency, signs of invasion. 3) Clinical N1 — nodal metastasis requires surgery (with therapeutic neck dissection). 4) Aggressive histology — tall cell, hobnail, columnar, sclerosing variants. 5) Strong family history — first-degree thyroid cancer; familial syndromes. 6) "Cold" nodule on scintigraphy with surgery preference; concurrent suspicious or non-well-differentiated pathology. 7) Patient not suitable for follow-up — socio-economic, geographic, motivational.

Age factor: <20 — may behave aggressively (and long lifetime surveillance burden), >60 — comorbidity may make surgery riskier but aggressive PTMC is rare; decision individualised. 40-60 is the "typical" surveillance candidate band.

Patient preference is central: surveillance is an informed shared decision — is the patient mentally/emotionally prepared for the stress of observation? Some want "we removed the cancer"; others want to avoid surgical complications. Both are medically reasonable.

Multidisciplinary review: endocrinology, head & neck/endocrine surgery, cytopathology (genetic testing in selected — BRAF, TERT, RAS). Joint review with the patient and family.

Practice in Turkey: surgery culturally remains the default; however, in large centres applying ATA guidelines (especially with combined endocrine surgery/endocrinology teams) active surveillance is increasingly used. Patient demand is also rising. For the related clinical reference, see thyroid cancer page.

Baseline workup: high-quality neck US (thyroid + central + lateral compartments), TSH, thyroglobulin, anti-Tg antibody, calcitonin (to exclude medullary), cytology (FNA — Bethesda VI papillary carcinoma), BRAF testing in selected cases.

Surveillance schedule: typical — neck US every 6 months for 2 years; then annually (if stable). TSH and thyroglobulin annually. Closer monitoring if any trend.

US criteria: nodule's three dimensions (length, width, depth — mm) and volume (V = π/6 × L × W × D) computed; baseline retained for comparison. Same operator/protocol preferred for high-quality serial imaging.

"Trigger" — conversion to surgery: 1) Size increase ≥3 mm in longest dimension. 2) Volume doubling (volumetric criterion). 3) New clinical nodal metastasis — central or lateral. 4) Sign of capsule/tracheal/nerve contact. 5) Change in patient preference — anxiety, quality of life, pregnancy plan, other medical conditions.

TSH suppression: not routine in active surveillance. Keep TSH within normal range (0.5-2.0 mIU/L preferred). Standard hypothyroid replacement when needed. Aggressive TSH suppression is not proven beneficial and risks osteoporosis, atrial fibrillation.

Patient responsibilities in surveillance: scheduled visits, symptom awareness (neck mass, voice change — urgent evaluation if these occur), date keeping (when next US), open communication channel.

Pregnancy: PTMC does not contraindicate pregnancy. More frequent (3-monthly) US is suggested during pregnancy — hormonal changes can rarely accelerate growth. Standard protocol resumes after delivery. If pregnancy is planned, joint endocrinology + obstetric assessment first.

Surgical options for PTMC: thyroid lobectomy (unilateral, contralateral normal), total thyroidectomy (bilateral disease, aggressive histology, syndromic). For PTMC ATA 2015 generally endorses lobectomy — total thyroidectomy is not routine.

Lymph node surgery: central compartment dissection (level VI) is therapeutic in clinical N1; prophylactic (clinical N0) is debated — some centres do it in aggressive cases, benefit unproven in most, raises hypoparathyroidism/RLN palsy risk.

Surgical complications: recurrent laryngeal nerve palsy (transient 3-5%, permanent 1-2%), hypoparathyroidism (transient 15-25%, permanent 1-3% with total thyroidectomy; rare with lobectomy), bleeding (<1%), infection, scar/keloid. Rates lower in high-volume centres.

After surgery: post-lobectomy — thyroid hormone need monitored; 20-30% require levothyroxine. Post-total — lifelong levothyroxine. Radioactive iodine (RAI) is not routine in low-risk PTMC.

Follow-up: post-surgery TSH, thyroglobulin (after total — tumour marker), annual neck US. Post-lobectomy contralateral lobe annual US.

Surgery vs surveillance: 10-year disease-specific mortality 0% in both; recurrence is mildly higher in surveillance but not clinically meaningful; surgical complications can affect life (RLN — voice, hypoparathyroidism — calcium). Quality-of-life comparison is individual.

Decision aid: family history concern — surgery; surveillance stress — surgery; surgical risk (age, comorbid) high — surveillance; cannot maintain regular follow-up — surgery. Ultimately both are safe — choice should match patient lifestyle and values. Related reading: our Istanbul thyroid surgery page.